Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: A north central cancer treatment group study

P. A. Burch, Matthew S Block, G. Schroeder, J. W. Kugler, D. J. Sargent, T. A. Braich, J. A. Mailliard, J. C. Michalak, A. K. Hatfield, K. Wright, S. A. Kuross

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

There continues to be a need for new systemic approaches for the treatment of advanced pancreatic cancer. The purpose of this study was to compare the antitumor activity of the somatostatin analogue octreotide to 5-fluorouracil chemotherapy in a Phase III setting. Eighty-four patients with an Eastern Cooperative Oncology Group performance status of 0 or 1 and limited tumor volume were randomized to receive octreotide 200 μg three times daily or 5-fluorouracil with or without leucovorin. After the first 12 patients had been randomized to octreotide, we increased the dose in the remaining patients to 500 μg three times daily. This change was based on early reports in other studies, suggesting that our original dose may not have been effective and that higher doses of octreotide were well tolerated. A planned interim analysis performed after 84 patients were enrolled demonstrated inferior time to progression and survival for the patients randomized to octreotide. Further accrual to the octreotide arm of this protocol was therefore terminated. Octreotide in doses of 200-500 μg three times daily does not delay progression or extend survival in patients with advanced pancreatic cancer compared with treatment with 5-fluorouracil with or without leucovorin.

Original languageEnglish (US)
Pages (from-to)3486-3492
Number of pages7
JournalClinical Cancer Research
Volume6
Issue number9
StatePublished - 2000

Fingerprint

Octreotide
Leucovorin
Pancreatic Neoplasms
Fluorouracil
Drug Therapy
Neoplasms
Therapeutics
Survival
Somatostatin
Tumor Burden

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer : A north central cancer treatment group study. / Burch, P. A.; Block, Matthew S; Schroeder, G.; Kugler, J. W.; Sargent, D. J.; Braich, T. A.; Mailliard, J. A.; Michalak, J. C.; Hatfield, A. K.; Wright, K.; Kuross, S. A.

In: Clinical Cancer Research, Vol. 6, No. 9, 2000, p. 3486-3492.

Research output: Contribution to journalArticle

Burch, PA, Block, MS, Schroeder, G, Kugler, JW, Sargent, DJ, Braich, TA, Mailliard, JA, Michalak, JC, Hatfield, AK, Wright, K & Kuross, SA 2000, 'Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: A north central cancer treatment group study', Clinical Cancer Research, vol. 6, no. 9, pp. 3486-3492.
Burch, P. A. ; Block, Matthew S ; Schroeder, G. ; Kugler, J. W. ; Sargent, D. J. ; Braich, T. A. ; Mailliard, J. A. ; Michalak, J. C. ; Hatfield, A. K. ; Wright, K. ; Kuross, S. A. / Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer : A north central cancer treatment group study. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 9. pp. 3486-3492.
@article{4478c268254b4abdbc6ca0a7e94dc90a,
title = "Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: A north central cancer treatment group study",
abstract = "There continues to be a need for new systemic approaches for the treatment of advanced pancreatic cancer. The purpose of this study was to compare the antitumor activity of the somatostatin analogue octreotide to 5-fluorouracil chemotherapy in a Phase III setting. Eighty-four patients with an Eastern Cooperative Oncology Group performance status of 0 or 1 and limited tumor volume were randomized to receive octreotide 200 μg three times daily or 5-fluorouracil with or without leucovorin. After the first 12 patients had been randomized to octreotide, we increased the dose in the remaining patients to 500 μg three times daily. This change was based on early reports in other studies, suggesting that our original dose may not have been effective and that higher doses of octreotide were well tolerated. A planned interim analysis performed after 84 patients were enrolled demonstrated inferior time to progression and survival for the patients randomized to octreotide. Further accrual to the octreotide arm of this protocol was therefore terminated. Octreotide in doses of 200-500 μg three times daily does not delay progression or extend survival in patients with advanced pancreatic cancer compared with treatment with 5-fluorouracil with or without leucovorin.",
author = "Burch, {P. A.} and Block, {Matthew S} and G. Schroeder and Kugler, {J. W.} and Sargent, {D. J.} and Braich, {T. A.} and Mailliard, {J. A.} and Michalak, {J. C.} and Hatfield, {A. K.} and K. Wright and Kuross, {S. A.}",
year = "2000",
language = "English (US)",
volume = "6",
pages = "3486--3492",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer

T2 - A north central cancer treatment group study

AU - Burch, P. A.

AU - Block, Matthew S

AU - Schroeder, G.

AU - Kugler, J. W.

AU - Sargent, D. J.

AU - Braich, T. A.

AU - Mailliard, J. A.

AU - Michalak, J. C.

AU - Hatfield, A. K.

AU - Wright, K.

AU - Kuross, S. A.

PY - 2000

Y1 - 2000

N2 - There continues to be a need for new systemic approaches for the treatment of advanced pancreatic cancer. The purpose of this study was to compare the antitumor activity of the somatostatin analogue octreotide to 5-fluorouracil chemotherapy in a Phase III setting. Eighty-four patients with an Eastern Cooperative Oncology Group performance status of 0 or 1 and limited tumor volume were randomized to receive octreotide 200 μg three times daily or 5-fluorouracil with or without leucovorin. After the first 12 patients had been randomized to octreotide, we increased the dose in the remaining patients to 500 μg three times daily. This change was based on early reports in other studies, suggesting that our original dose may not have been effective and that higher doses of octreotide were well tolerated. A planned interim analysis performed after 84 patients were enrolled demonstrated inferior time to progression and survival for the patients randomized to octreotide. Further accrual to the octreotide arm of this protocol was therefore terminated. Octreotide in doses of 200-500 μg three times daily does not delay progression or extend survival in patients with advanced pancreatic cancer compared with treatment with 5-fluorouracil with or without leucovorin.

AB - There continues to be a need for new systemic approaches for the treatment of advanced pancreatic cancer. The purpose of this study was to compare the antitumor activity of the somatostatin analogue octreotide to 5-fluorouracil chemotherapy in a Phase III setting. Eighty-four patients with an Eastern Cooperative Oncology Group performance status of 0 or 1 and limited tumor volume were randomized to receive octreotide 200 μg three times daily or 5-fluorouracil with or without leucovorin. After the first 12 patients had been randomized to octreotide, we increased the dose in the remaining patients to 500 μg three times daily. This change was based on early reports in other studies, suggesting that our original dose may not have been effective and that higher doses of octreotide were well tolerated. A planned interim analysis performed after 84 patients were enrolled demonstrated inferior time to progression and survival for the patients randomized to octreotide. Further accrual to the octreotide arm of this protocol was therefore terminated. Octreotide in doses of 200-500 μg three times daily does not delay progression or extend survival in patients with advanced pancreatic cancer compared with treatment with 5-fluorouracil with or without leucovorin.

UR - http://www.scopus.com/inward/record.url?scp=0033822686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033822686&partnerID=8YFLogxK

M3 - Article

C2 - 10999733

AN - SCOPUS:0033822686

VL - 6

SP - 3486

EP - 3492

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 9

ER -